Cardiovascular and renal developments: Patent highlights to January to June 2006

Current Opinion in Investigational Drugs

Volumn 7, Issue 9, 2006, Pages 792-798

  Mucke, Hermann A M ^a  

^a HM Pharma Consultancy   (Austria)

Author keywords

Cardiovascular; Coagulation; Factor Xa; Renal; Thrombosis

Indexed keywords

2 (3,4,5 TRIHYDROXY 6 HYDROXYMETHYLTETRAHYDROPYRAN 2 YLOXY)PHENYLALANINE DERIVATIVE; 2 ALKOXYBENZAMIDE; ADENOSINE A1 RECEPTOR AGONIST; ADENOSINE A3 RECEPTOR AGONIST; ANTIOXIDANT; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; CARBONYL DERIVATIVE; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; CINNAMIC ACID DERIVATIVE; DICARBOXAMIDE DERIVATIVE; FLUOROPHOSPHONOCINNAMIC ACID DERIVATIVE; HETEROARYLACETAMIDE DERIVATIVE; HETEROCYCLIC COMPOUND; HYDRAZIDE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOINDOLE DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA ANTAGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ANTAGONIST; PROLINE DERIVATIVE; PYRIDINE DERIVATIVE; SELENOPHENYL; SMALL INTERFERING RNA; THIOPHENECARBOXAMIDE DERIVATIVE; THIOPHENYL; THROMBIN INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASOPRESSIN ANTAGONIST; VASOPRESSIN V2 ANTAGONIST;

AGING; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELL BASED GENE THERAPY; CHRONIC DISEASE; DISEASE EXACERBATION; DISEASE MODEL; DRUG INDUSTRY; DRUG RESPONSE; DRUG TARGETING; ENZYME INHIBITION; GENE TARGETING; GENE THERAPY; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HEART MUSCLE CELL; HUMAN; HYPERTENSION; INDUSTRIALIZATION; KIDNEY DISEASE; MORTALITY; NONHUMAN; ONSET AGE; PATENT; PATIENT MONITORING; REVIEW; STEM CELL;

ANIMALS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; DRUG DESIGN; GENE THERAPY; HUMANS; KIDNEY DISEASES; RENAL AGENTS; RNA, SMALL INTERFERING; TISSUE THERAPY;

EID: 33748714054     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Artesian Therapeutics Inc (Taylor GM, Klenke B, Suzdak PD, Mazhari R): New dual pharmacophore 2-hydroxyethylamine derivatives are β-adrenergic antagonists and/or phosphodiesterase inhibitors - useful for the treatment of cardiovascular diseases, stroke, epilepsy, ophthalmic disorders and migraine. WO-2006060122 (2006).
2. Stocker RO: New aryl substituted compounds - useful for the treatment of cardiovascular disorders such as atherosclerosis, restenosis and hypertension. WO-2006063408 (2006).
3. Janssen Pharmaceutica NV (Maryanoff B, Matthews J): New bicyclic [1,4]benzodiazepine derivatives are vasopressin V2 antagonists - useful for the treatment of hypertension, cardiac insufficiency, coronary vasospasm, cirrhosis, renal failure, stroke, thrombosis and water retention. WO-2006049984 (2006)
4. Arena Pharmaceuticals Inc (Boatman DP, Schrader TO, Semple G, Skinner PJ, Jung J-K): New fused pyrazole derivatives are RUP26 receptor agonists - useful for the treatment of metabolic-related disorders such as atherosclerosis, dyslipidemia and coronary heart disease. WO-2006069242 (2006).
5. Merck & Co Inc (Colletti SL, Tata JR, Shen HC, Ding F-X, Frie JL, Imbriglio JE, Chen W): New biaryl derivatives are niacin agonists - useful for the treatment of dysilpidemia and atherosclerosis. WO-2006057922 (2006)
6. SmithKline Beecham Corp (Hatley RJD, Pinto IL): New xanthine derivatives are HM74A receptor modulators - useful for the treatment of eg diabetic dyslipidemia, heart failure and atherosclerosis. WO-2006045564 (2006).
7. SmithKline Beecham Corp (Hatley RJD, Pinto IL): New xanthine derivatives are HM74A receptor modulators - useful for the treatment of, eg, diabetic dyslipidemia, heart failure and atherosclerosis. WO-2006045565 (2006).
8. Sanofi-Aventis Deutschland GmbH (Knieps S, Englert HC, Gerlach U, Goegelein H, Heitsch H, Lehr K-H, Pfeiffer-Marek S): New piperidine sulfonyl urea derivatives are blockers of ATP-sensitive potassium channels - useful for the treatment of cardiovascular disorders. WO-2006063722 (2006).
9. Xention Discovery Limited (Ford J, Madge DJ, Palmer NJ, Atherall JF, John D): New thieno[2,3-b]pyridine derivatives are potassium channel inhibitors - useful for the treatment and prevention of arrhythmia, type 1 and 2 diabetes and immune, inflammatory bowel and demyelinating disorders. WO-2006061642 (2006).
10. Devgen NV (Biom P, De Kerpel JO, Fourmaintraux E, René PP, Kaletta, TJ, Leysen D): Novel thiazole-5-carboxamide derivatives are selective Kv channel blockers - useful for the treatment of cardiac and central nervous system disorders. WO-2006068905 (2006).
11. Cell Signals Inc/National University Corp/Nagoya University (Mitsuru H, Itsuo, K. Takashi M, Kenji K): Composition comprising midklne protein - useful for the treatment of heart disease. WO-2006062087 (2006).
12. Japan Tobacco Inc (Hirata K, Ogawa N, Shinagawa Y, Kiguchi T, Inoue T, Matsuo A, Kosugi Y, Nomura Y, Kawahara I, Uehara H): Use of a nitrogenous fused compound as a URAT1 Inhibitor - for treating, eg, hyperuricemia, gouty node, acute or chronic gouty arthritis, gouty kidney, urinary calcus, renal dysfunction, coronary artery disease and ischemic artery disease. WO-2006057460 (2006).
13. SmithKline Beecham Corp (Frazee JS, Hammond M, Kano K, Manns S, Nakamura H, Thompson SK, Washburn DG): New 1H-pyrrol[2,3-b]pyridine derivatives are SGK-1 kinase inhibitors - useful for the treatment of proliferative disorders, water retention, renal disease or cardiovascular disease. WO-2006063167 (2006).
14. Bayer Healthcare AG (Hendrix M, Zimmermann K, Hirth-Dietrich C, Karig G, Karthaus D, Raabe M, Weber O, Zaiss S): New substituted 1,2,4-triazin-5(2H)-ones are PAF acetylhydrolase inhibit - useful for the treatment of chronic inflammatory disease, cardiovascular disease and arteriosclerosis. WO-2006063811 (2006).
15. Bayer Healthcare AG (Hendrix M, Zimmermann K, Hirth-Dietrich C, Karig G, Karthaus D, Raabe M, Weber O, Zaiss S): New 3-cycloalkyl-1,2,4-triazin-5(2H)-ones are PAF acetylhydrolase inhibitors - useful for the treatment of chronic inflammatory disease, cardiovascular disease and arteriosclerosis. WO-2006063812 (2006).
16. Bayer Healthcare AG (Hendrix M, Zimmermann K, Hirth-Dietrich C, Karig G, Karthaus D, Raabe M, Weber O, Zaiss S): New 3-arylalkyl-and 3-heteroarylalkyl-substituted 1,2,4-triazin-5(2H)-ones are PAF acetylhydrolase inhibitors - useful for the treatment of chronic inflammatory disease, cardiovascular disease and arteriosclerosis. WO-2006063813 (2006).
17. Bayer Healthcare AG (Hendrix M, Zimmermann K, Flessner T, Hirth-Dietrich C, Karig G, Raabe M, Karthaus D, Michels M, Weber O, Zaiss S, Zumpe F): New 3-benzylthio-1,2,4-triazin-5(2H)-one compounds are PAF acetylhydrolase inhibitors - useful for the treatment of chronic inflammatory disease, cardiovascular disease and arteriosclerosis. WO-2006063791 (2006).
18. 2 inhibitors - Useful for the prevention and treatment of cardiovascular disease such as hyperlipidemia, coronary artery heart disease and atherosclerosis. US-20060106017 (2006).
19. The Kitasato Institute (Omura S, Tomoda H, Masuma R): New macrocyclic macrophage foaming inhibitor - useful for treating and preventing atherosclerosis, myocardial infarction, cerebral apoplexy and cerebral stroke. WO-2006048947 (2006).
20. Dade Behring Marburgh GmbH (Althaus H, Schwarz H, Fischer B, Wissel T): Antibodies directed against the FSAP Marburg I variant - useful for diagnosing atherosclerotic disease. US-20080045879 (2006).
21. UCL Biomedica plc (Vallance P, John T, Leiper J, Mitchell S, David L, Rossiter S, Hartzoulakis B): New N-alkylguanadinylamino acid derivatives are dimethylarginine dimethylaminohydrolase inhibitors - used to treat eg ischemia, sepsis, pain and neurodegeneration. WO-2006051314 (2006).
22. Zernike Business Support BV (Henning RH, Kampinga HH, Brundel BJJM): Method for preventing or delaying damage to a cardiac cell induced by a supraventricular arrhythmia - comprises increasing the amount of heat shock protein in the cardiac cell. WO-2006062402 (2006).
23. Myogen Inc (Bush E, Hood D): Use of a modulator of muscle selective calcineuron interacting protein (MCIP-1-38) - for the treatment of cardiovascular disease. WO-2006034184 (2006).
24. Benitec Inc (Couto L, Brashears S, Cunningham SM): Methods for delivering RNAi agents to target genes in vascular and surrounding tissue - useful for treating restenosis. US-20060115454 (2006).
25. Alnylam Pharmaceuticals Inc (Soutschek J, Vorniocher H-P, Hadwiger P, Elbashir S): Interfering RNA agent capable of reducing the amount of ApoB mRNA - useful for treating lipid disorders, eg, hypercholesterolemia, hyperlipidemia and coronary artery disease. WO-2006036916 (2006).
26. Noxxon Pharma AG (Purschke W, Eulberg D, Klussmann S, Röhl I, Vater A): Vasopressin-binding nucleic acids - useful for treating, eg, congestive heart failure. WO-2006058705 (2006).
27. Anges MG Inc (Sam Y, Shirakawa Y, Tatsumi E, Taenaka Y, Matsuda H): Vector encoding an angiogenic cytokine - useful in the gene therapy of heart disease. WO-2006046766 (2006).
28. Kumamoto University (Yorinaka H, Ding J-F, Meng X-M): Use of MAP kinase TNN13K - for the treatment of heart disease. WO-2006057278 (2006).
29. Aharinejad S: Use of colony stimulating factor-1 enhanced myoblasts - for the treatment of ischemic heart diseases and heart failure. WO-2006047799 (2006).
30. Columbia University In The City Of New York/The Research Foundation Of State University Of New York (Cohen IS, Rosen MR, Robinson RB, Brink PR, Gaudette G, Potapova I): Use of a cardiogenic cell - for treating a cardiac disorder eg myocardial infarction. WO-2006032054 (2006).
31. The Johns Hopkins University (Li RA, Akar FG, Cho H, Marban E, Tomaselli G): Method for modifying rhythmic electrical and contractile activities of in vivo cardiac tissue - comprises integrating the donor cardiomyocytes derived from genetically engineered human embryonic stem cells into recipient cardiomyocytes. WO-2006017567 (2006).
32. IP Organisers Pty Ltd/ ES Cell International Pte Ltd (Passier R, Mummery CL): Methods for inducing differentiation of human embryonic stem cells - useful for producing cardiomyocytes and cardiomyocyte progenitor cells. WO-2006066320 (2006).
33. Technion Research & Development Foundation Ltd (Gerecht-Nir S, Itskovitz-Eldor J): Method of generating vascular smooth muscle cells from vasculogenic progenitor cells - comprises culturing the progenitor cells in a differentiating medium including a serum volume concentration higher than 5%. WO-2006040755 (2006).
34. INSERM/TxCell (Groux H, Tedgui A, Mallat Z, Brun V): Use of an antigen capable of activating in vitro a Tr1 cell population, and the Tr1 cell population activated by the antigen - for treating or preventing atherosclerosis. WO-2006018674 (2006).
35. Tibotec Pharmaceuticals Ltd (Kesteleyn BRR, Raboisson PJ-M, Van De Vreken W, Canard MFJ-MG): New 1,5,6-substituted-2-oxo-3-cyano-1,6a-diaza-tetrahydro-fluoranthene derivatives are reverse transcriptase inhibitors - useful for the treatment of retroviral diseases. WO-2006039630 (2006).
36. University of Medicine and Dentistry of New Jersey (Vatner SF, Depre C): Method for identifying an agent for modulating cell growth or survival - comprises determining the net ratio of nuclear-localized versus cytosolic-localized H11 kinase in a cell contacted with a test agent. WO-2006036822 (2006).
37. Nattel S, Hebert T: Method for identifying a compound for treating atrial fibrillation - comprises selecting the compound that inhibits tachyarrhythmias in the atrial preparation isolated from the heart of the mammal. US-20060094003 (2006).
38. University of Rochester (Berk BC, Abe J-I): Transgenic non-human models of ischemia/reperfusion injury - useful for screening for agents for treating ischemic disorders. WO-2006050532 (2006).
39. Japan Health Sciences Foundation (Iida H, Ohta Y, Teramoto N, Hayashi T): Construction of arterial occlusive disease animal model. WO-2006030737 (2006).
40. University of Yamanashi (Sugiyama A, Takahara A, Hashimoto K): Method of constructing animal model of atrial fibrillation, method of inducing atrial fibrillation and method of evaluating atrial fibrillation inhibitor. WO-2006025450 (2006).
41. Cordis Corp (Argentieri DC, Falotico R, Parry TJ, Zhao JZ): Method for evaluating pathologies in a rat carotid artery - comprises endovascularly creating an injury within the carotid artery of a rat and evaluating the pathologies associated with the injury. US-20060104903 (2006).
42. F Hoffmann-La Roche AG (Boehringer M, Groebke KZ, Haap W, Hilpert H, Panday N, Ricklin F): New heteroarylacetamide derivates are Factor Xa inhibitors - useful for treatment of thrombotic disorders and tumors. WO-2006066778 (2006).
43. Hoffmann-La Roche Inc (Boehringer M, Zbinden KG, Haap W, Hilpert H, Panday N, Ricklin F): Heteroarylacetamide inhibitors of Factor Xa. US-20060142362 (2006).
44. F Hoffmann-La Roche AG (Boehringer M, Groebke KZ, Haap W, Hilpert H, Himber J, Humm R, Iding H, Hilpert H, Knopp D, Panday N, Ricklin F, Stahl CM): New dicarboxamide derivatives are Factor Xa antagonists - useful for the treatment of, eg, thrombotic disorders, inflammation and tumors. WO-2006048152 (2006).
45. Morphochem Aktiengesellschaft für Kombinatorische Chemie (Fuchs T, Eckl R): New 2-(3,4,6-trihydroxy-6-hydroxymethyl-tetrahydropyran-2-ylioxy) phenylalanine derivatives are Factor Xa inhibitors - useful for the treatment and prevention of thromboembolytic diseases, arterial restenosis, blood poisoning, cancer and acute inflammation. WO-2006008141 (2006).
46. Bristol-Myers Squibb Co (Glunz PW, Wurtz N, Cheng X): New heterocyclic amine derivatives are inhibitors of Factor VIIa, IXa, Xa, XIa and/or plasma kalllkrein - useful for the treatment of thromboembolic disorders. WO-2006062972 (2006).
47. Portola Pharmaceuticals Inc (Song Y, Zhu B-Y, Wang S, Bauer S, Scarborough RM): New tetrahydroisoquinoline derivatives are Factor Xa inhibitors - useful for inhibiting blood coagulation and treating thrombotic disorders. WO-2006055951 (2006).
48. Portola Pharmaceuticals Inc (Song Y, Zhu B-Y, Wang S, Bhakta C, Scarborough RM): New urea derivatives are Factor Xa inhibitors - useful for the treatment of thrombosis and related conditions. WO-2006063113 (2006).
49. Portola Pharmaceuticals Inc (Song Y, Zhu B-Y, Bhakta C, Scarborough RM): New thiourea derivatives are Factor Xa inhibitors - useful for the treatment of thrombosis and related conditions. WO-2006063293 (2006).
50. Portola Pharmaceuticals Inc (Scarborough RM, Venkatraman MS, Zhang X, Pandey A): New substituted 2H-1,3-benzoxazin-4(3H)-one derivatives are platelet ADP receptor inhibitors - useful for treating thrombosis and secondary ischemic events. US-20060069093 (2006).
51. Bayer Healthcare AG (Röhrig S, Pohlmann J, Arndt S, Jeske M, Akbaba M, Perzborn E, Gerdes C, Schlemmer K-H, Tuch A, Lobell M, Nell P, Burkhardt N): New cyclic iminocarbamate derivatives are Factor Xa inhibitors - useful as anticoagulants for the treatment and prevention of thromboembolic disorders. WO-2006058630 (2006).
52. Janssen Pharmaceutica NV (Lu T, Thieu TV, Player MR, Lee Y-K, Parks DJ, Markotan TP, Pan W, Milkiewicz KL): New bicyclic derivatives are Factor Xa inhibitors - useful for the treatment of cardiovascular diseases associated with thromboses. WO-2006047415 (2006).
53. Eli Lilly & Co (Argade AB, Goodson T Jr, Herron DK, Joseph S, Lepore SD, Marquart AL, Masters JJ, Mendel DML, Ratz AM, Smith GF, Tebbe AL): New 2-alkoxybenzamide and related derivatives are Factor Xa and/or thrombin inhibitors - useful for the treatment of thromboembolic disorders. WO-2006057845 (2006).
54. Eli Lilly & Co (Franciskovich JB, Herron DK, Wimkowski VJ, Marquart AL, Masters JJ, Mendel D, Ratz AM, Smith GF, Wiley MR, Yee YK): New 2-alkoxybenzamide derivatives are Factor Xa and/or thrombin inhibitors - useful for the treatment of thromboembolic disorders. WO-2006057868 (2006).
55. Corte JR, Li Y-L: Novel cyclic β-amino acid as inhibitors of Factor Xa and thrombin - useful in the treatment of thromboembolic disorders. US-20060074103 (2006).
56. Merck Patent GmbH (Cezanne B, Dorsch D, Mederski W, Tsaklakidis C, Gleitz J): New carbonyl compounds are Factor Xa and Factor VIIa antagonists - useful for the treatment of, eg, thrombosis, myocardial infarction, inflammation, apoplexy, restenosis, migraine and tumor metastasis. WO-2006034769 (2006).
57. Merck Patent GmbH (Cezanne B, Dorsch D, Mederski W, Tsaklakidis C, Gleitz J): New carbonyl compounds are coagulation inhibitors - useful for the treatment of, eg, thrombosis, inflammation, restenosis, migraine and cancer. WO-2006032342 (2006).
58. Boehringer Ingelheim International GmbH (Priepke H, Gerlach K, Pfau R, Wienen W, Schuler-Metz A, Nar H, Handschuh S): New substituted thiophene carboxamides are thrombin and Factor Xa inhibitors - useful for the treatment of, eg, DVT, reocclusions after bypass operations, pulmonary embolism and ulcerative colitis. US-20060069082 (2006).
59. Sanofi-Aventis (Duchaussoy P, Herault JP, Herbert JM, Petitou M, Savi P): New biotinylated hexadecasaccharide derivatives are Factor IIa and Factor Xa antagonists - useful for the treatment of coagulation disorders. WO-2006030104 (2006).
60. Daiamed Inc (Deng H, Lin J, Guo Z, Meyers HV, Abdel-Meguid SS, Babine RE): New indole compounds - useful for treating thromboembolic disorders. WO-2006012504 (2006).
61. Santhera Pharmaceuticals (Schweiz) GmbH (Bosio S, Bulat S, Feurer A, Rosenbaum C, Matassa VG): New aminopyridines are thrombin antagonists - useful for the treatment of thrombosis and cardiovascular diseases. WO-2006045459 (2006).
62. National University Of Singapore (Kini MR, Koh CY, Joseph JS): Isolated peptide derived from trocarin protein and capable of interacting with factor Va - useful for preventing formation of intravascular blood clots in subjects having ischemic events. WO-2006049580 (2006).
63. Eisai Co Ltd (Clark R, Hirota S, Azuma H, Kira K, Watanabe N, Nagakura T, Harizoe T): New hydrazide derivatives are activated Factor VII inhibitors and antithrombotic agents - useful for treating diseases in which thrombosis is a factor such as deep vein thrombosis, pulmonary thrombosis, cerebral infarction, myocardial infarction and reperfusion disorder. WO-2006041119 (2006).
64. Wyeth (Commons TJ, Jenkins DJ): New pyrroionaphthalene derivatives are PAI-1 inhibitors - useful for the treatment of eg fibrinolytic disorders and cardiovascular disease. WO-2006023864 (2006).
65. Wyeth (Commons TJ, Woodworth RP Jr): New oxazolonaphthalene derivatives are PAI-1 inhibitors - useful for the treatment of fibrinolytic disorders and cardiovascular disease. WO-2006023865 (2006).
66. Wyeth (Commons TJ): New thiazolonaphthalene derivatives are PAI-1 inhibitors - useful for the treatment of fibrinolytic disorders and cardiovascular disease WO-2006023866 (2006).
67. Novartis AG, Novartis Pharma GmbH (Breitenstein W, Cottens S, Ehrhardt C, Jacoby E, Lorthiois ELJ, Maibaum JK, Ostermann N, Sellner H, Simic O): New pyrrolidine derivatives are renin inhibitors - useful for the treatment of cardiovascular diseases, diabetic complications and cognitive disorders. WO-2006066896 (2006).
68. Actelion Pharmaceuticals Ltd (Bezencon O, Bur D, Fischli W, Remen L, Richard-Bildstein S, Sifferlen T, Weber H-P, Weller T): New diazabicyclononene derivative, a non-peptide renin inhibitor - useful for the treatment of, eg, hypertension, congestive heart failure, renal insufficency, glaucoma and cognitive disorders. WO-2006061791 (2006).
69. Actelion Pharmaceuticals Ltd (Bezencon O, Remen L, Sifferlen T, Grisostomi C, Richard-Bildstein S, Bur D, Boss C, Corminboeuf O, Fischil W, Weller T): New lactam derivatives are renin inhibitors - useful for the treatment of, eg, cardiovascular disorders, renal disease and diabetic complications. WO-2006058546 (2006).
70. Actelion Pharmaceuticals Ltd (Bezencon O, Boss C, Bur D, Corminboeuf O, Fischli W, Grisostomi C, Remen L, Richard-Bildslein S, Sifferlen T, Weller T): New bicyclic derivatives are renin inhibitors - useful for the treatment of, eg, cardiovascular disorders, renal disease and diabetic complications. WO-2006059304 (2006).
71. Actelion Pharmaceuticals Ltd (Bezencon O, Boss C, Bur D, Corminboeuf O, Fischli W, Grisostomi C, Remen L, Richard S, Sifferlen T, Weller T): New diazabicyclononene and related derivatives are renin inhibitors - useful for the treatment of, eg, cardiovascular diseases and renal failure. WO-2006021399 (2006).
72. Actelion Pharmaceuticals Ltd (Bezencon O, Boss C, Bur D, Corminboeuf O, Fischli W, Grisostomi C, Remen L, Richard S, Sifferlen T, Weller T): New diazabicyclononene and related derivatives are renin inhibitors - useful for the treatment of, eg, cardiovascular diseases and renal failure. WO-2006021403 (2006).
73. Actelion Pharmaceuticals Ltd (Bezencon O, Boss C, Bur D, Corminboeuf O, Fischli W, Grisostomi C, Remen L, Richard S, Sifferlen T, Weller T): New diazabicyclononene and related derivatives are renin inhibitors - useful for the treatment of, eg, cardiovascular diseases and renal failure. WO-2006021402 (2006).
74. Actelion Pharmaceuticals Ltd (Bezencon O, Boss C, Bur D, Corminboeuf O, Fischli W, Grisostomi C, Remen L, Richard S, Sifferlen T, Weller T): New diazabicyclononene and related derivatives are renin inhibitors - useful for the treatment of, eg, cardiovascular diseases and renal failure. WO-2006021401 (2006).
75. Speedel Experimenta AG (Herold P, Stutz S, Mah R, Tschinke V, Marti C): New ω-phenyloctanamide derivatives are renin inhibitors - useful for the treatment of, eg, hypertension and heart failure. WO-2006061426 (2006).
76. Speedel Experimenta AG (Herold P, Stutz S, Mah R, Tschinke V, Marti C): New